Russia says that the country will register its first vaccine by August 12 which is developed by Moscow’s Gamaleya Research Institute of Epidemiology and Microbiology. The health ministry of India stated that two of the indigenous vaccines are in clinical trials. One will be tested on 11,050 subjects at 8 sites and the other will be on 1000 subjects at 5 sites. In the meantime, more than 165 potential COVID vaccines and 27 experimental vaccines have been tested at different stages across the world.
UK’s Oxford-AstraZeneca, US-based Moderna, Pfizer-BioNTech, Chinese firms Sinovac and Sinopharm, and India’s indigenous COVAXIN are the vaccines which grabbed more attention from the public. The phase 1 and phase 2 trials of Covaxin has experimented across 12 places in India with different candidates.
The Gamaleya vaccine in Russia is likely to receive the conditional registration by August. The vaccine will be first administered only to health professionals and the production is likely to begin by September. The CEO of Serum Institute of India Aadar Poonawalla has already stated that Astra Zeneca’s vaccine cost will be around 1000 in India and the vaccine will be out with its name ‘Covishield’. On the other hand, Monderna’s vaccine is expected to be out with the price around Rs 3700- Rs 4500. But the vaccine with this price will be affordable only in high-income countries.
various scientists and pharma companies are breaking their heads all over the world to fight against this pandemic. Even if the vaccine is out in the future will people accept it completely? many issues even after the release of vaccines will arise definitely. Will countries like India will be able to afford the facilities for the whole country. Pool of ideas using in your mind? Be free to express and the platform is here. Drop your valuable suggestions in the comment box.
Click HOME to read more interesting articles.